Research at Fox Chase »Technology Transfer »Symposium

« Symposium Agenda

Fox Chase Cancer Center
Research and Technology Symposium

Tuesday May 20
8:30am – 5:30pm
The Academy of Natural Sciences
1900 Benjamin Franklin Parkway
Philadelphia

Research topics presented during the Symposium:

• cell signaling modification in tumors progression resulting from metastasis and drug resistance;
  
• exploitation of engineered antibody fragments to detect and treat solid tumors;
  
• characterization of the genetic changes in cancer cells;
  
• evaluation of normal gene function and pathogenesis of cancer cells to assess cancer prevention, diagnosis, and treatment;
  
• biological relevance, involvement, and regulation of signaling pathways that operate through Rho proteins;
  
• involvement of protein phosphorylation in governing the proliferative and morphologic transformation of cancer;
  
• development of new cancer treatments with fewer side effects, with an emphasis on gastrointestinal, breast and genitourinary cancers;
  
• signal transduction crosstalk between Killer Cell Inhibitory Receptors (KIR) and KIR2DL4, and involvement of KIR2DL4 in natural killer cell responses toward tumors and virus-infected cells;
  
• investigation of basic paths of viral infection of the CNS (access, replication, progress, and role of the immune response) and their consequences on the host;
  
• elaboration of computational structural biology models, such as homology modeling, fold recognition, molecular dynamics simulations, statistical analysis, and bioinformatics, to study DNA repair, membrane proteins, proteases and other peptide-binding protein families;
  
• refinement and analysis of mouse models of epithelial ovarian cancer to identify and study the underlying genetic causes of tumor initiation and progression;
  
• involvement of gene activation and cell differentiation in mammalian development;
  
• establishment of preclinical programs to develop efficacious regimens for the clinical prevention of colon, lung and oral cancer;
  
• evaluation of biological implications of recurrent genomic alterations occuring in malginant mesotheliomas;
  
• analysis of intracellular functions of two proteins encoded by the TSC1 and TSC2 gene, responsible for causing the tuberous sclerosis complex disease;
  
• investigation of pre-T cell antigen receptor (TCR) activation and its development into the mature TCR complex;
  
• overview of the Fox Chase phase I/II clinical research capabilities and programs.

For more information, contact the Fox Chase Office of Corporate Alliances.